Evidence map›Paper›PMID 41877717›Full record

ArticleMolecular therapy. Oncology2026

Vinorelbine enhances the efficacy of oncolytic vaccinia virus in a preclinical model of ovarian high-grade serous carcinoma.

Stephanie Drymiotou, Christophe J Queval, Katherine E Tyson, Lesley A Sheach, Antonio Postigo, Ilaria Dalla Rosa, Darren P Ennis, Michael Howell, Iain A McNeish, Michael Way

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Stephanie DrymiotouCellular Signalling and Cytoskeletal Function Laboratory, The Francis Crick Institute, London NW1 1AT, UK.
Christophe J QuevalHigh Throughput Screening Laboratory, The Francis Crick Institute, London NW1 1AT, UK.
Katherine E TysonOvarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College London, W12 0HS, UK.
Lesley A SheachCellular Signalling and Cytoskeletal Function Laboratory, The Francis Crick Institute, London NW1 1AT, UK.
Antonio PostigoCellular Signalling and Cytoskeletal Function Laboratory, The Francis Crick Institute, London NW1 1AT, UK.
Ilaria Dalla RosaCellular Signalling and Cytoskeletal Function Laboratory, The Francis Crick Institute, London NW1 1AT, UK.
Darren P EnnisOvarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College London, W12 0HS, UK.
Michael HowellHigh Throughput Screening Laboratory, The Francis Crick Institute, London NW1 1AT, UK.
Iain A McNeishOvarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College London, W12 0HS, UK.
Michael WayCellular Signalling and Cytoskeletal Function Laboratory, The Francis Crick Institute, London NW1 1AT, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vaccinia virus, known for its clinical safety, has a tropism for primary and metastatic tumors as well as ovarian tissue. Consequently, oncolytic approaches with recombinant vaccinia viruses have emerged as attractive agents against ovarian cancer. Unfortunately, oncolytic vaccinia monotherapies are yet to live up to their potential promise. Given this, there is a need to identify combination agents that improve the effectiveness of vaccinia in ovarian cancer treatment. We screened 9,000 compounds to identify drugs that enhance the ability of a recombinant vaccinia virus lacking VGF and F1 (ΔVF) to induce death of ID8

Indexed as

combination therapiesoncolytic agentovarian cancervaccinia virus

Identifiers

PMID41877717
PMCPMC13006439

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.